Literature DB >> 15820810

Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study.

Ilse A J van Rooij1, Frank J M Broekmans, Gabrielle J Scheffer, Caspar W N Looman, J Dik F Habbema, Frank H de Jong, Bart J C M Fauser, Axel P N Themmen, Egbert R te Velde.   

Abstract

OBJECTIVE: The aim of this study was to assess which of the basal ovarian reserve markers provides the best reflection of the changes occurring in ovarian function over time (i.e., reproductive aging).
DESIGN: Prospective longitudinal study.
SETTING: Healthy volunteers in an academic research center. PATIENT(S): Eighty-one women with normal reproductive performance during the course of their lives were longitudinally assessed. In this select group of women, becoming chronologically older was considered as a proxy variable for becoming older from a reproductive point of view. INTERVENTION(S): The women were assessed twice, with on average a 4-year interval (T(1) and T(2)). The number of antral follicles on ultrasound (AFC) and blood levels of antimullerian hormone (AMH), FSH, inhibin B, and E(2) were assessed. MAIN OUTCOME MEASURE(S): Longitudinal changes of the markers mentioned and the consistency of these parameters over time. RESULT(S): The mean ages at T(1) and T(2) were 39.6 and 43.6 years, respectively. Although AFC was strongly associated with age in a cross-sectional fashion, it did not change over time. The AMH, FSH, and inhibin B levels showed a significant change over time, in contrast to E(2) levels. The AMH and AFC were highly correlated with age both at T(1) and T(2), whereas FSH and inhibin B predominantly changed in women more than 40 years of age. To assess the consistency of these parameters over time, we investigated whether a woman's individual level above or below the mean of her age group at T(1) remained above or below the mean of her age group at T(2). Serum AMH concentrations showed the best consistency, with AFC as second best. The FSH and inhibin B showed only modest consistency, whereas E(2) showed no consistency at all. CONCLUSION(S): These results indicate that serum AMH represents the best endocrine marker to assess the age-related decline of reproductive capacity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820810     DOI: 10.1016/j.fertnstert.2004.11.029

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  136 in total

1.  Anti-Müllerian hormone: a potential new tool in epidemiologic studies of female fecundability.

Authors:  Donna D Baird; Anne Z Steiner
Journal:  Am J Epidemiol       Date:  2012-01-12       Impact factor: 4.897

2.  Impact of cancer therapies on ovarian reserve.

Authors:  Clarisa R Gracia; Mary D Sammel; Ellen Freeman; Maureen Prewitt; Claire Carlson; Anushree Ray; Ashley Vance; Jill P Ginsberg
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

3.  Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).

Authors:  Megan E B Clowse; Susannah C Copland; Tsung-Cheng Hsieh; Shein-Chung Chow; Gary S Hoffman; Peter A Merkel; Robert F Spiera; John C Davis; W Joseph McCune; Steven R Ytterberg; E William St Clair; Nancy B Allen; Ulrich Specks; John H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-12       Impact factor: 4.794

4.  Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.

Authors:  Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers
Journal:  J Clin Endocrinol Metab       Date:  2012-02-16       Impact factor: 5.958

5.  The original Beckman Coulter Generation II assay significantly underestimates AMH levels compared with the revised protocol.

Authors:  Michael Bonifacio; Cara K Bradley; Sonal Karia; Mark Livingstone; Mark C Bowman; Steven J McArthur
Journal:  J Assist Reprod Genet       Date:  2015-10-14       Impact factor: 3.412

6.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

Review 7.  Ovarian reserve evaluation: state of the art.

Authors:  Bruno Ramalho de Carvalho; Ana Carolina Japur de Sá Rosa e Silva; Júlio César Rosa e Silva; Rosana Maria dos Reis; Rui Alberto Ferriani; Marcos Felipe Silva de Sá
Journal:  J Assist Reprod Genet       Date:  2008-08-05       Impact factor: 3.412

Review 8.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

9.  Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles.

Authors:  Lauren Johnson; Mary D Sammel; Allison Schanne; Lara Lechtenberg; Maureen Prewitt; Clarisa Gracia
Journal:  Fertil Steril       Date:  2016-09-22       Impact factor: 7.329

10.  A proteomic analysis of IVF follicular fluid in women <or=32 years old.

Authors:  Stephanie J Estes; Bin Ye; Weiliang Qiu; Daniel Cramer; Mark D Hornstein; Stacey A Missmer
Journal:  Fertil Steril       Date:  2008-11-05       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.